Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

Concomitant medications and efficacy of nintedanib in patients with IPF

Michael Kreuter, Jin Woo Song, John T. Huggins, Benoit Wallaert, Wibke Stansen, Manuel Quaresma, Bruno Crestani
European Respiratory Journal 2017 50: PA4891; DOI: 10.1183/1393003.congress-2017.PA4891
Michael Kreuter
1Center for interstitial and rare lung diseases, Pneumology, Thoraxklinik, University of Heidelberg, and Translational Lung Research Center Heidelberg, German Center for Lung Research, Heidelberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jin Woo Song
2ASAN Medical Center, Seoul, Republic of Korea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John T. Huggins
3Medical University of South Carolina, Charleston, South Carolina, United States of America
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Benoit Wallaert
4University Hospital of Lille, Lille, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wibke Stansen
5Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Manuel Quaresma
6Center for interstitial and rare lung diseases, Pneumology, Thoraxklinik, University of Heidelberg, and Translational Lung Research Center Heidelberg, German Center for Lung Research; and Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bruno Crestani
7Hôpital Bichat, Pneumologie, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
Loading

Abstract

Introduction: In the two INPULSIS trials in patients with IPF, the annual rate of decline in FVC was reduced in patients treated with nintedanib 150 mg twice daily versus placebo. Patients who completed an INPULSIS trial could receive open-label nintedanib in the extension trial INPULSIS-ON. The influence of medications commonly prescribed to treat comorbid conditions on the effect of nintedanib is unknown.

Aim: To assess whether concomitant medication use at the start of INPULSIS and INPULSIS-ON influenced the effect of nintedanib on FVC decline.

Methods: The annual rate of decline in FVC over 52 weeks in INPULSIS and over 48 weeks in INPULSIS-ON in subgroups defined by concomitant medication use at baseline was assessed descriptively.

Results: The annual rates of decline in FVC over 52 weeks in INPULSIS and over 48 weeks in INPULSIS-ON were consistent across subgroups by concomitant medication use at baseline, including anti-acid therapy and corticosteroids (Table). There was a numerical difference in the annual rate of decline in FVC between subgroups defined by use of N-acetylcysteine or bronchodilators in INPULSIS-ON; however, as the number of patients in some subgroups was small, these results should be interpreted with caution.

Conclusion: Data from INPULSIS and INPULSIS-ON demonstrated a consistent effect of nintedanib on the annual rate of decline in FVC in patients with IPF irrespective of concomitant medication use at baseline.

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint

  • Copyright ©the authors 2017
Previous
Back to top
Vol 50 Issue suppl 61 Table of Contents
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Concomitant medications and efficacy of nintedanib in patients with IPF
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Concomitant medications and efficacy of nintedanib in patients with IPF
Michael Kreuter, Jin Woo Song, John T. Huggins, Benoit Wallaert, Wibke Stansen, Manuel Quaresma, Bruno Crestani
European Respiratory Journal Sep 2017, 50 (suppl 61) PA4891; DOI: 10.1183/1393003.congress-2017.PA4891

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Concomitant medications and efficacy of nintedanib in patients with IPF
Michael Kreuter, Jin Woo Song, John T. Huggins, Benoit Wallaert, Wibke Stansen, Manuel Quaresma, Bruno Crestani
European Respiratory Journal Sep 2017, 50 (suppl 61) PA4891; DOI: 10.1183/1393003.congress-2017.PA4891
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo

Jump To

  • Article
  • Figures & Data
  • Info & Metrics
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Tolerability and efficacy of Pirfenidone and Nintedanib for patients with IPF in real world clinical practice
  • Fatigue in patients with idiopathic pulmonary fibrosis (IPF) from the pooled pirfenidone (PFD) Phase III trials
  • Collaborating with stakeholders to advance the National Patient Charter for Idiopathic Pulmonary Fibrosis in Ireland
Show more Diffuse Parenchymal Lung Disease

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society